Ardelyx (ARDX): FDA Will Have "Difficult Time Justifying Another Rejection" - Piper Sandler Bullish Post AdCom Vote
Tweet Send to a Friend
Piper Sandler analyst Christopher Raymond upgraded Ardelyx, Inc (NASDAQ: ARDX) from Neutral to Overweight with a price target of $8.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
